Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

Completed · Phase 1

Conditions studied: Hypertension

In brief

The goal of this Phase 1, open-label, single-dose, parallel-group study is to evaluate the pharmacokinetics (PK) of a single 10-mg oral dose of baxdrostat in subjects with varying degrees of hepatic function. The main objectives are to: * To assess the safety and tolerability of baxdrostat following administration of a single oral dose of baxdrostat to subjects with varying degrees of hepatic function; and * To characterize the PK of baxdrostat following administration of a single oral dose of baxdrostat to subjects with varying degrees of hepatic function. Participants were administered a single 10-mg oral dose of baxdrostat in the fasted state the morning of Day 1. Plasma samples were drawn at various timepoints. Safety assessments included adverse events, vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory evaluations, and physical examinations. Twenty subjects in 2 groups based on the Child-Pugh classification in the protocol at screening: up to 10 subjects in the normal hepatic function group and up to 10 subjects in the moderate hepatic impairment group. Twenty subjects entered and completed the study.

Key facts

Study ID

NCT05961397

Run by

AstraZeneca

People needed

20

Starts

2021-08-10

Expected to finish

2022-04-15

Last updated by the study team

2023-08-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Is between the ages of 18 and 80 years, inclusive, and in stable health condition. (For hepatically impaired subjects, their hepatic function category must be stable for a minimum of 3 months prior to screening.)
• Is a non-nicotine user or smokes =<10 cigarettes/day;
• Has a BMI between 18 and 42 kg/m2, inclusive;
• Is able to understand and willing to comply with study procedures and restrictions and provide written informed consent;
• if a male subject with a female partner of childbearing potential must agree to use 2 medically accepted, highly effective methods of birth control for 90 days.
• if male, must agree to abstain from sperm donation for 90 days; and
• if female with a male partner, must be surgically sterile, postmenopausal, or agree to use 2 medically accepted, highly effective methods of birth control from Day -14 until 60 days after study drug dosing
• Main Exclusion Criteria:
• Personal or family history of long QT syndrome, torsades de pointes, or other complex ventricular arrhythmias, or family history of sudden death;
• History of, or current, clinically significant arrhythmias;
• Prolonged QTcF (>460 msec) based on the average of triplicate ECGs;
• Estimated glomerular filtration rate (or creatinine clearance) <50 mL/min/1.73 m2;
• Evidence of any of the following: Encephalopathy grade 2 or worse, Seated systolic BP >160 mmHg and/or diastolic BP >100 mmHg, or systolic BP <90 mmHg and/or diastolic BP <50 mmHg, resting heart rate >100 beats per minute (bpm) or <50 bpm, Oral temperature >37.6°C (>99.68°F), Respiration rate <12 or >20 breaths per minute, symptomatic postural tachycardia or orthostatic hypotension, abnormal serum potassium >upper limit of normal range, abnormal serum sodium <130 mEq/L, positive test for HIV antibody, hepatitis C , hepatitis B , or SARS-CoV-2 RNA
• Current treatment with weight loss medication or prior weight loss surgery;
• Use of a moderate or strong inhibitor of CYP3A4 within 14 days prior to the dose of study drug OR use of a moderate or strong inducer of CYP3A4 within 28 days prior to the dose of study drug;
• Corticosteroid use (systemic or extensive topical use) within 3 months prior to study drug dosing
• Pregnant, breastfeeding, or planning to become pregnant during the study

Where it is running

• Inland Empire Clinical Trials — Rialto, California, United States
• Advanced Pharma CR — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Alliance for Multispecialty Research — Knoxville, Tennessee, United States
• American Research Corporation at the Texas Liver Institute — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.